NEW YORK (
) hit a new 52-week low Thursday as it is currently trading at $25.69, below its previous 52-week low of $26.46 with 17,656 shares traded as of 9:36 a.m. ET. Average volume has been 899,500 shares over the past 30 days.
Salix has a market cap of $1.6 billion and is part of the
industry. Shares are down 43.4% year to date as of the close of trading on Wednesday.
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company has a P/E ratio of 37.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.
- Practice your SLXP trading strategies and win cash in our stock game.
TheStreet Ratings rates Salix as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. You can view the full
or get investment ideas from our